CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,000 target
Drug / intervention
Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01460186
NCT01460186N/ACompleted
CompareCT.gov

Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer : a Multicenter Non-randomized Prospective Cohort Study

Centre Leon Berard·interventional·Posted Oct 26, 2011·Updated Jan 15, 2019

In Brief

A clinical study evaluating Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer) for Breast Cancer and Metastasis. Completed, enrolled 1,000 participants across 17 sites.

Detailed Summary

This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify germ line genetic factors that influence the risk of metastatic breast cancer. 1500 patients will be enrolled in this study. Blood samples will be collected after informed consent and inclusion in the study. Patients will be treated and followed according to the standards of their treating center. They will be followed during at least 5 years every 6 months for 3 years then every year.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Metastasis
CountriesFrance
CollaboratorsCancer Research Center of Lyon

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 26, 2011
Enrollment StartDec 1, 2011
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 14.7 years ago

Interventions

Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)other

Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.